Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa
- 1Northumbria Healthcare Trust, Tyne and Wear, UK
- 2Applied Immunobiology and Transplantation Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
- Correspondence to Robert Rutherford, North Tyneside General Hospital, Rake Lane, North Shields, Tyne and Wear NE29 8NH, UK;
- Accepted 5 July 2009
Colonisation with Pseudomonas aeruginosa is a feature of bronchiectasis and is associated with more severe disease and lower quality of life.1 Nebulised colomycin, a polymixin, bactericidal antibiotic with potent activity against most Gram-negative organisms, including P aeruginosa, is frequently employed in these patients, but evidence is lacking for this approach.
We have retrospectively assessed the efficacy of nebulised colomycin in P aeruginosa-colonised patients receiving a minimum of 6 months treatment. Patients who received concomitant prophylactic macrolide treatment for >4 weeks were excluded. Bronchiectasis was confirmed in all patients by standard high-resolution CT criteria, and all received nebulised colomycin 1–2 megaunits twice daily through a standard jet nebuliser …